CRP and COVID-19: However, we emphasize that initial evidence of Tocilizumab among hospitalized COVID-19 patients demonstrating shortened hospital stays and lower mortality rates remains clinically impactful and that the significant drop in CRP levels allows to assess in a practical way the response to treatment with Tocilizumab on a specific level of severity of the disease group of patients.